Researchers have identified a biomarker that can help determine which medlinkrenal cancer/medlink patients are at a higher risk of recurrence. The
Vous n'êtes pas connecté
The gene signature for renal cancer can help clinicians identify recurrence risk earlier and potentially guide patient treatment strategies.
Researchers have identified a biomarker that can help determine which medlinkrenal cancer/medlink patients are at a higher risk of recurrence. The
Researchers at the University of Michigan Rogel Cancer Center have developed a 15-gene signature that helps classify clear cell kidney cancer patients...
A novel AI approach can accurately detect six different types of cancer on whole-body PET/CT scans, according to research presented at the 2024...
Steatotic (fatty) liver disease is on the rise in many countries around the world. A rise in steatotic liver disease comes with an increase in the...
Breast cancer is a complex disease with varying degrees of severity and treatment approaches. Central to understanding and managing breast cancer is...
An analysis of data from a randomised clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib,...
Treatment outcomes for breast cancer have become better over the years, but proportion of breast cancers still recur even after long periods without...
Researchers have identified a Vascular Endothelial Growth Factor Receptor (VEGFR) that could lead to new treatments for colon and renal cancers. ...
Fewer than one percent of people who get the flu every year get tested, in part because most tests require trained personnel and expensive...
Artificial intelligence (AI) may help doctors to detect and diagnose cancer in patients that will allow for earlier treatment, reports a new study. ...